{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:04:13Z","timestamp":1756512253431,"version":"3.44.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"name":"VA National Oncology Program Office"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>UV-related DNA damage signature (UVsig) is highly specific for cutaneous cancers. The prevalence of UVsig among tumors without a primary site and tumors of extracutaneous origin were previously reported, suggesting potential misclassification of cancers. Our study aims to assess if the knowledge of UVsig at diagnosis would change first-line treatment recommendation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The main outcome was the potential clinical impact (PCI) of UVsig. High PCI was defined as UVsig leading to change in diagnosis and first-line therapy. Medium PCI was a change in diagnosis, but appropriate therapy was offered. Low PCI group had diagnosis modified by clinicians and treated as cutaneous cancer independently of UVsig.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 5565 cases, 650 (12%) were positive for a UVsig. In the cancer of unknown primary group: 20 (49%), 9 (22%), and 12 (29%) cases were categorized in the high, medium, and low PCI group, respectively. In the cancer of extracutaneous origin cohort: 22 (54%), 15 (36%), and 4 (10%) cases were high, medium, and low PCI, respectively. The diagnosis would have changed in 14% of Veterans with UVsig positive tumor. Among all high PCI cases, 37 (88%) received chemotherapy that was not indicated based on a UVsig-informed diagnosis of cutaneous malignancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study suggested that UVsig would lead to revision of the working clinical diagnosis and significantly alter the first-line treatment in at least half of cancers of unknown primary or extracutaneous origin with UVsig. Knowledge of UVsig could lead to more effective and less toxic therapy for patients with cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae335","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T19:30:23Z","timestamp":1734204623000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of UV mutational signatures in Veterans with cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8100-363X","authenticated-orcid":false,"given":"Ni-Chi","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Veterans Affairs, VA National Oncology Program . Durham, NC ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S P","family":"Huang","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc. , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Lin","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA National Oncology Program . Durham, NC ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan S","family":"Sokol","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc. , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine N","family":"Serway","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA National Oncology Program . Durham, NC ,","place":["United States"]},{"name":"Danaher Diagnostics , Washington, DC ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc. , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc. , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Kelley","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA National Oncology Program . Durham, NC ,","place":["United States"]},{"name":"Division of Hematology-Oncology, Durham VA Medical Center , Durham, NC ,","place":["United States"]},{"name":"Division of Medical Oncology, Department of Medicine, Duke University , Durham, NC ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"2025082905271800800_CIT0001","doi-asserted-by":"crossref","first-page":"e223833","DOI":"10.1001\/jamanetworkopen.2022.3833","article-title":"Prevalence of UV mutational signatures among cutaneous primary tumors","volume":"5","author":"Mata","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025082905271800800_CIT0002","first-page":"PO.18.00002","article-title":"Mutational signature and transcriptomic classification analyses as the decisive diagnostic tools for a cancer of unknown primary","volume":"2","author":"Bagge","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025082905271800800_CIT0003","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1002\/hed.25613","article-title":"Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site","volume":"41","author":"Chan","year":"2019","journal-title":"Head Neck"},{"key":"2025082905271800800_CIT0004","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/s41379-020-0594-0","article-title":"Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma","volume":"33","author":"Yang","year":"2020","journal-title":"Mod Pathol"},{"key":"2025082905271800800_CIT0005","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.21037\/jtd-20-2602","article-title":"Mutational signatures in squamous cell carcinoma of the lung","volume":"13","author":"Osoegawa","year":"2021","journal-title":"J Thorac Dis"},{"journal-title":"American Cancer Society","author":"Key Statistics for Cancers of Unknown Primary","key":"2025082905271800800_CIT0006"},{"key":"2025082905271800800_CIT0007","doi-asserted-by":"crossref","first-page":"e1883","DOI":"10.7205\/MILMED-D-16-00371","article-title":"Cancer incidence among patients of the U.S. Veterans affairs health care system: 2010 update","volume":"182","author":"Zullig","year":"2017","journal-title":"Mil Med"},{"key":"2025082905271800800_CIT0008","first-page":"PO.19.00075","article-title":"Genomic analysis of metastatic solid tumors in Veterans: findings from the VHA national precision oncology program","volume":"3","author":"Poonnen","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2025082905271800800_CIT0009","first-page":"S22","article-title":"VA national precision oncology program","volume":"37","author":"Kelley","year":"2020","journal-title":"Fed Pract"},{"key":"2025082905271800800_CIT0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Rampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2025082905271800800_CIT0011","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/bioinformatics\/btx604","article-title":"Detecting presence of mutational signatures in cancer with confidence","volume":"34","author":"Huang","year":"2018","journal-title":"Bioinformatics"},{"key":"2025082905271800800_CIT0012","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1089\/cmb.2021.0453","article-title":"ScalpelSig designs targeted genomic panels from data to detect activity of mutational signatures","volume":"29","author":"Franzese","year":"2022","journal-title":"J Comput Biol"},{"key":"2025082905271800800_CIT0013","doi-asserted-by":"crossref","first-page":"e1005965","DOI":"10.1371\/journal.pcbi.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"2025082905271800800_CIT0014","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","article-title":"Deciphering signatures of mutational processes operative in human cancer","volume":"3","author":"Alexandrov","year":"2013","journal-title":"Cell Rep"},{"key":"2025082905271800800_CIT0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Alam","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025082905271800800_CIT0016","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjd.19621","article-title":"British association of dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020","volume":"184","author":"Keohane","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025082905271800800_CIT0017","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","article-title":"Diagnosis and treatment of merkel cell carcinoma: European consensus-based interdisciplinary guideline-update 2022","volume":"171","author":"Gauci","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025082905271800800_CIT0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025082905271800800_CIT0019","doi-asserted-by":"crossref","first-page":"e2200692","DOI":"10.1200\/PO.22.00692","article-title":"Real-world experience with neurotrophic tyrosine receptor kinase fusion-positive tumors and tropomysin receptor kinase inhibitors in Veterans","volume":"7","author":"Zhou","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025082905271800800_CIT0020","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/1878-0261.12748","article-title":"Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy","volume":"14","author":"Pham","year":"2020","journal-title":"Mol Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae335\/61184013\/oyae335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae335\/61184013\/oyae335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:27:26Z","timestamp":1756459646000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae335\/7924197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae335","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,12,15]]},"article-number":"oyae335"}}